Effects of cannabis on opioid withdrawal in individuals with opioid use disorder
Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Abuse Potential and Safety
PHASE1 · University of Kentucky · NCT05729932
This study is testing whether inhaled cannabis can help people with opioid use disorder feel better during withdrawal.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | University of Kentucky (other) |
| Locations | 1 site (Lexington, Kentucky) |
| Trial ID | NCT05729932 on ClinicalTrials.gov |
What this trial studies
This study aims to enroll participants diagnosed with opioid use disorder who are not currently seeking treatment. It will assess the effects of inhaled vaporized cannabis on opioid withdrawal symptoms and related outcomes. The study will utilize a Phase 1 interventional approach to evaluate the safety and efficacy of cannabis in this population. Participants will receive both cannabis and intranasal opioids as part of the intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a current diagnosis of opioid use disorder who are not actively seeking treatment.
Not a fit: Patients with current medical conditions that require medical management may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel treatment option for managing opioid withdrawal symptoms.
How similar studies have performed: While there is ongoing research into cannabis for various conditions, this specific approach to treating opioid use disorder is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Current opioid use disorder Exclusion Criteria: * Current medical conditions that require medical management
Where this trial is running
Lexington, Kentucky
- Center on Drug and Alcohol Research — Lexington, Kentucky, United States (RECRUITING)
Study contacts
- Principal investigator: Shanna Babalonis, PhD — University of Kentucky
- Study coordinator: Paul Nuzzo, MA
- Email: pnuzz2@email.uky.edu
- Phone: 859-323-0002
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Opioid Use Disorder